Monoclonal Antibodies and Immunoassay for Medical Plant-Derived Natural Products: A Review

Abstract

Owing to the widespread application value, monoclonal antibodies (MAbs) have become a tool of increasing importance in modern bioscience research since their emergence. Recently, some researchers have focused on the production of MAbs against medical plant-derived natural products (MPNP), the secondary metabolites of medical plants. At the same time, various immunoassay methods were established on the basis of these MPNP MAbs, and then rapidly developed into a novel technique for medical plant and phytomedicine research in the area of quality control, pharmacological analysis, drug discovery, and so on. Dependent on the research works carried out in recent years, this paper aims to provide a comprehensive review of MAbs against MPNP and the application of various immunoassay methods established on the basis of these MAbs, and conclude with a short section on future prospects and research trends in this area.

Immunoaffinity separation of miroestrol and deoxymiroestrol from Pueraria candollei var. mirifica (Airy Shaw & Suvat.) Niyomdham using fragment antigen‐binding antibody produced via Escherichia coli

“…This may have resulted from increased binding sites of the monoclonal antibody (IgG), which consists of two Fab units. The reported capacity of IAC using monoclonal antibodies against plant‐derived natural products varies from micrograms to milligrams of pure compound per 1 mL of gel 24 . The low efficacy of immunoaffinity chromatography may be attributed to the low level of Fab immobilised onto the Ni‐NTA column.…”

Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials

“…In 1975, Köhler and Milstein were the first to produce anti-sheep red cell monoclonal antibodies. They developed a method to produce monoclonal antibodies via a method called the hybridoma technique 1 . In recent years, MAbs have remarkably improved the treatment outcomes for a wide variety of human diseases, including inflammatory and neoplastic diseases 2 .…”

Preparing molecularly imprinted nanoparticles of saponins via cooperative imprinting strategy

“…However, because of the low immunogenicity of the glycosyl chains of saponins [12], antibodies for saponins are very limited. For example, only a few antibodies for the well‐known triterpenoid saponins (ginsenosides) have been reported [13,14]. Owing to the presence of imprinted cavities complementary to the templates, molecularly imprinted polymers (MIPs) can provide affinity and specificity toward the templates [15–22].…”